Lyra Therapeutics (LYRA) Tax Provisions (2023 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Tax Provisions of -$6.1 million in Q4 2025, down 202733.33% on a QoQ basis from $3000.0 in Q3 2025, and up 69.06% YoY from -$3.6 million in Q4 2024.
Lyra Therapeutics (LYRA) Tax Provisions (2023 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Tax Provisions for 3 consecutive years, with -$6.1 million the latest figure, recorded in Q4 2025.
- Tax Provisions for Q4 2025 came in at -$6.1 million, up 69.06% year-over-year; the trailing twelve-month figure through Dec 2025 was -$6.1 million (up 69.05% YoY), and the FY2025 annual result was -$6.1 million, up 69.05% from the prior year.
- Tax Provisions for Q4 2025 stood at -$6.1 million, down from $3000.0 in the prior quarter.
- The five-year high for Tax Provisions was $17000.0 in Q4 2023, with the low at -$19.6 million in Q4 2024.
- A 3-year average of -$2.1 million and a median of $9500.0 in 2023 frame the typical range for Tax Provisions.
- Across the five-year window, Tax Provisions slumped 115670.59% in 2024 and jumped 69.06% in 2025, its largest moves.
- Lyra Therapeutics' Tax Provisions stood at $17000.0 in 2023, then tumbled by 115670.59% to -$19.6 million in 2024, then jumped by 69.06% to -$6.1 million in 2025.
- The last three Tax Provisions figures came in at -$6.1 million (Q4 2025), $3000.0 (Q3 2025), and $2000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -6.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.08 Mn |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | -19.65 Mn |
| Sep 30, 2024 | 7,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Sep 30, 2023 | 16,000.00 |
| Jun 30, 2023 | 12,000.00 |
| Mar 31, 2023 | 14,000.00 |